Nonlinear optical limiting effect of porous graphene dispersions at 1064 nm.

This work presents a new, to the best of our knowledge, porous graphene dispersion in ethanol that can achieve a good nonlinear optical limiting (NOL) effect at the wavelength of 1064 nm. Using the Z-scan system, the nonlinear absorption coefficient of the porous graphene dispersion with a concentration of 0.01 mg/mL was measured as 9.69×10-9 c m/W. The NOL of the porous graphene dispersions in ethanol under three different concentrations (0.01, 0.02, and 0.03 mg/mL) were measured. Among them, the 1-cm-thick porous graphene dispersion with a concentration of 0.01 mg/mL has the best optical limiting effect, in which the linear transmittance is 76.7%, and the lowest transmittance is 24.9%. By using the pump-probe technique, we detected the formation and annihilation times of the scatter when the suspension interacts with the pump light. The analysis shows that the NOL mechanisms of the novel porous graphene dispersion are mainly nonlinear scattering and nonlinear absorption.

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients.

BACKGROUND: Heart failure (HF) is one of the most serious health concerns worldwide. Anemia is a highly prevalent comorbidity and outcome predictor in HF patients. Sodium glucose co-transport 2 (SGLT2) inhibitors have been demonstrated to reduce the risk of cardiovascular death and HF hospitalization in HF patients. PURPOSE: This investigator-initiated, interventional, prospective, double-blind, multicenter study is designed to investigate whether anemia correction is one of the prerequisites and determinants related to the beneficial effects of dapagliflozin in HF patients. METHODS AND RESULTS: Up to 2030 HF participants receiving standard care will be randomly assigned to either oral dapagliflozin 10 mg once daily or placebo 10 mg once daily for 12 months. The primary outcome is the composite incidence of hospital admission for HF and all-cause death. Secondary outcomes include change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score and change in 6-min walk distance and hemoglobin level. Patients will be followed for 12 months after randomization. CONCLUSIONS: The ADIDAS trial offers an opportunity to assess the hemoglobin change and association between hemoglobin change and readmissions due to heart failure and all-cause death in patients with heart failure treated with dapagliflozin or placebo. This study could highlight if dynamic hemoglobin change is related to the outcome for HF patients. TRIAL REGISTRATION: ClinicalTrials.gov ; NCT04707261. Registration date, 2020/12/01, "retrospectively registered".

Nonlinear optical limiting effect of graphene dispersions at 1064 nm.

We study the nonlinear optical limiting effect of graphene dispersions in ethanol and acetone at a wavelength of 1064 nm. The nonlinear optical limiting effect of graphene dispersion under three different linear transmittances (about 70%, 80%, and 90%), two different thicknesses (1 and 3 cm), and two different solvents (ethanol and acetone) are measured. The influences of concentration, thickness, and solvent on the nonlinear optical limiting effect of the graphene dispersion are analyzed. The experimental results show that the concentration and solution thicknesses have great influence on the optical limiting ability of graphene dispersions. The graphene dispersions with ethanol and acetone as solvents can be used to achieve excellent nonlinear optical limiting effects. The optical limiting ability of the graphene dispersion in acetone is better than that of the graphene dispersion in ethanol.